Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Cited by (7,578)

Items 801–900 of 7,578

1. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin.
   Lingvay, Ildiko, Desouza, Cyrus V., Lalic, Katarina S., Rose, Ludger, Hansen, Thomas, Zacho, Jeppe, Pieber, Thomas R. · 2018 · Diabetes Care
2. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
   Chen, Jia-Jin, Wu, Chao-Yi, Jenq, Chang-Chyi, Lee, Tao-Han, Tsai, Chung-Ying, Tu, Hui-Tzu, Huang, Yu-Tung, Yen, Chieh-Li, Yen, Tzung-Hai, Chen, Yung-Chang et al. · 2022 · JAMA Network Open
3. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
   Robyn Bruen, Seán Curley, Sarina Kajani, Daniel Crean, Marcella E. O'Reilly, Margaret B. Lucitt, Catherine Godson, Fiona C. McGillicuddy, Orina Belton · 2017 · Cardiovascular Diabetology
4. Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
   Stuart J. McGurnaghan, Luke A. K. Blackbourn, Emina Mocevic, Ulrik Haagen Panton, Rory J. McCrimmon, Naveed A. Sattar, Sarah H. Wild, Helen Martina Colhoun · 2018 · Diabetic Medicine
5. Albumin-based drug designs for pharmacokinetic modulation
   Diego Pilati, Kenneth Alan Howard · 2020 · Expert Opinion on Drug Metabolism & Toxicology
6. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
   Stephen Brunton, Carol Wysham · 2020 · Postgraduate Medicine
7. Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
   Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik · 2022 · International Journal of Molecular Sciences
8. Childhood Obesity, Diabetes, and Cardiovascular Disease Risk
   Mostafa Salama, Babu Balagopal, Ilene Fennoy, Seema Kumar · 2023 · The Journal of Clinical Endocrinology & Metabolism
9. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
   Ishani Kapoor, Swara M. Sarvepalli, David A. D’Alessio, Dilraj Singh Grewal, Majda Hadziahmetovic · 2023 · Survey of Ophthalmology
10. Mechanisms of diabetic kidney disease and established and emerging treatments
    Victor Martinez Leon, Rachel Hilburg, Katalin Suszták · 2025 · Nature Reviews Endocrinology
11. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress
    Guang Yang, Yanna Lei, Aiko Inoue, Limei Piao, Lina Hu, Haiying Jiang, Takeshi Sasaki, Hongxian Wu, Wenhu Xu, Chenglin Yu et al. · 2017 · Atherosclerosis
12. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · Diabetologia
13. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
    Irace, Concetta, Casciaro, Francesco, Scavelli, Faustina Barbara, Oliverio, Rosa, Cutruzzolà, Antonio, Cortese, Claudio, Gnasso, Agostino · 2018 · Cardiovascular Diabetology
14. Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
    Nikolic, Dragana, Giglio, Rosaria Vincenza, Rizvi, Ali A., Patti, Angelo Maria, Montalto, Giuseppe, Maranta, Francesco, Cianflone, Domenico, Stoian, Anca Pantea, Rizzo, Manfredi · 2021 · Diabetes Therapy
15. Oral semaglutide in type 2 diabetes
    Sarah L. Anderson, Trevor R. Beutel, Jennifer M. Trujillo · 2020 · Journal of Diabetes and its Complications
16. Strategies for participant retention in long term clinical trials
    Subramani Poongothai, Ranjit Mohan Anjana, Ramasamy Aarthy, Ranjit Unnikrishnan I, K.M. Venkat Narayan, Mohammed K. Ali, Kulasegaran Karkuzhali, Viswanathan Mohan · 2022 · Perspectives in Clinical Research
17. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial
    Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, Tanja Vukajlovic, Katja Bologna, Michelle Steinmetz, Cemile Bathelt, Clara Odilia Sailer, D. Vogt et al. · 2023 · EClinicalMedicine
18. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
    Ilaria Dicembrini, Besmir Nreu, Alessia Scatena, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2017 · Acta Diabetologica
19. Heart failure with preserved ejection fraction: current management and future strategies
    Carsten Tschöpe, Christoph M. Birner, Michael Böhm, Oliver Bruder, Stefan Frantz, Andreas Luchner, Lars Siegfried Maier, Stefan Störk, Behrouz Kherad, Ulrich Laufs · 2017 · Clinical Research in Cardiology
20. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
    Shih‐Chieh Shao, Kai‐Cheng Chang, Ming‐Jui Hung, Ning-I Yang, Yuk‐Ying Chan, Hui‐Yu Chen, Yea‐Huei Kao Yang, Edward Chia‐Cheng Lai · 2019 · Cardiovascular Diabetology
21. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
    Yumin Gao, Eric David Peterson, Neha Jadeja Pagidipati · 2020 · American Heart Journal
22. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
    Dan Atar, J. Wouter Jukema, Bart Molemans, Pam R. Taub, Shinya Goto, François Mach, Cesar Cerezo Olmos, James A. Underberg, ANTHONY C. KEECH, Lale S Tokgözoğlu et al. · 2021 · Atherosclerosis
23. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
    Adam J. Nelson, Neha Jadeja Pagidipati, Vanita R. Aroda, Matthew Aaron Cavender, Jennifer B. Green, Renato D. Lópes, Hussein R. Al‐Khalidi, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk et al. · 2021 · Circulation
24. Impact of Obesity in Kidney Diseases
    Vasilios Kotsis, Fernando Martínez, Christina Trakatelli, Josep Redón · 2021 · Nutrients
25. Advances in the management of chronic kidney disease
    Teresa K. Chen, Melanie P. Hoenig, Dorothea Nitsch, Morgan Erika Grams · 2023 · BMJ
26. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
    Abdul Waheed Khan, Karin Agnes Maria Jandeleit-Dahm · 2025 · Nature Reviews Cardiology
27. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
    Tian, Feng, Zheng, Zhigang, Zhang, Damin, He, Si, Shen, Jie · 2018 · Bioscience Reports
28. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao et al. · 2017 · Cardiovascular Diabetology
29. Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis
    Huilin Tang, Guangyao Li, Ying Jiao Zhao, Fei Wang, Emily West Gower, Luwen Shi, Tiansheng Wang · 2018 · Diabetes Obesity and Metabolism
30. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
    Daniel J. Drucker · 2018 · Diabetes
31. Clinical management of type 2 diabetes in south Asia
    Anoop Misra, Naveed A. Sattar, Nikhil Tandon, Usha Shrivastava, Naval K. Vikram, Kamlesh K. Khunti, Andrew Peter Hills · 2018 · The Lancet Diabetes & Endocrinology
32. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α
    M. Ahsan Siraj, Dhanwantee Mundil, Sanja Beca, Abdul Momen, Eric A. Shikatani, Talat Afroze, Xuetao Sun, Ying Liu, Siavash Ghaffari, Warren L. Lee et al. · 2020 · Journal of Clinical Investigation
33. Health wearable devices for weight and BMI reduction in individuals with overweight/obesity and chronic comorbidities: systematic review and network meta-analysis
    Daniel J. McDonough, Xiwen Su, Zan Gao · 2021 · British Journal of Sports Medicine
34. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
    Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, James R. Sowers, Wenshuo Wang, Junbo Ge, Jun Tao Ren, Yingmei Zhang · 2022 · Journal of Molecular Cell Biology
35. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
    Stefano Romeo, Antonio Vidal‐Puig, Mansoor Husain, Rexford S. Ahima, Marcello Arca, Deepak L. Bhatt, Anna Mae Diehl, Luigi Fontana, Roger Foo, Gema Frühbeck et al. · 2025 · European Heart Journal
36. An update on DPP-4 inhibitors in the management of type 2 diabetes
    Avivit Cahn, Simona Cernea, Itamar Raz · 2016 · Expert Opinion on Emerging Drugs
37. Telemedicine in Primary Care for Patients With Chronic Conditions: The ValCrònic Quasi-Experimental Study
    Domingo Orozco‐Beltrán, Manuel Sánchez-Molla, Julio Jesús Sánchez García, José Joaquín Mira · 2017 · Journal of Medical Internet Research
38. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
    James G. Boyle, Rachel Livingstone, John R. Petrie · 2018 · Clinical Science
39. Cardiovascular outcome trials in obesity: A review
    Wilding, John P.H., Jacob, Stephan · 2021 · Obesity Reviews
40. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: A multicentre randomized superiority trial
    Hulst, Abraham H., Visscher, Maarten J., Godfried, Marc B., Thiel, Bram, Gerritse, Bastiaan M., Scohy, Thierry V., Bouwman, R. Arthur, Willemsen, Mark G. A., Hollmann, Markus W., Preckel, Benedikt et al. · 2020 · Diabetes, Obesity and Metabolism
41. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2021 · Cardiovascular Diabetology
42. Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke
    Nizari, Shereen, Basalay, Marina, Chapman, Philippa, Korte, Nils, Korsak, Alla, Christie, Isabel N., Theparambil, Shefeeq M., Davidson, Sean M., Reimann, Frank, Trapp, Stefan et al. · 2021 · Basic Research in Cardiology
43. 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
    Kittleson, Michelle M., Benjamin, Emelia J., Blumer, Vanessa, Harrington, Josephine, Januzzi, James L., McMurray, John J.V., Vest, Amanda R. · 2025 · JACC
44. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
    Muhammad A Abdul‐Ghani, Amin Jayyousi, Ralph A. DeFronzo, Nidal Asaad, Jassim M. S. Al Suwaidi · 2017 · Current Vascular Pharmacology
45. Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
    Patrick Meagher, Mohamed Adam, Robert Civitarese, Antoinette Bugyei‐Twum, Kim Alexander Connelly · 2018 · Canadian Journal of Cardiology
46. Worsening Heart Failure During the Use of DPP-4 Inhibitors
    Milton Packer · 2018 · JACC Heart Failure
47. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
    Peter R Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F. Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr P. Ponikowski et al. · 2021 · The Lancet Diabetes & Endocrinology
48. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial
    Pandey, Ambarish, Patel, Kershaw V., Segar, Matthew W., Ayers, Colby, Linge, Jennifer, Leinhard, Olof D., Anker, Stefan D., Butler, Javed, Verma, Subodh, Joshi, Parag H. et al. · 2024 · Journal of Cachexia, Sarcopenia and Muscle
49. Glucagon and heart in type 2 diabetes: new perspectives
    Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda · 2016 · Cardiovascular Diabetology
50. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes
    Romera, Irene, Cebrián-Cuenca, Ana, Álvarez-Guisasola, Fernando, Gomez-Peralta, Fernando, Reviriego, Jesús · 2019 · Diabetes Therapy
51. Weight Loss Medications in the Treatment of Obesity and Hypertension
    Jordana B. Cohen, Kishore M. Gadde · 2019 · Current Hypertension Reports
52. The incretin/glucagon system as a target for pharmacotherapy of obesity
    Del Prato, Stefano, Gallwitz, Baptist, Holst, Jens Juul, Meier, Juris J. · 2022 · Obesity Reviews
53. Catalase and nonalcoholic fatty liver disease
    Su‐Kyung Shin, Hyun-Woo Cho, Seung-Eun Song, Dae‐Kyu Song · 2018 · Pflügers Archiv - European Journal of Physiology
54. Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
    Al-Salameh, Abdallah, Chanson, Philippe, Bucher, Sophie, Ringa, Virginie, Becquemont, Laurent · 2019 · Mayo Clinic Proceedings
55. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial
    Katrine Hygum, Torben Harsløf, Niklas Rye Jørgensen, Jørgen Rungby, Steen B. Pedersen, Bente Lomholt Langdahl · 2019 · Bone
56. Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
    Roua Iorga, Nicolae Bacalbașa, Mara Carşote, Ovidiu Gabriel Bratu, Ana Maria Alexandra Stănescu, SIMONA GABRIELA BUNGAU, Carmen Pantiș, Camelia Cristina Diaconu · 2020 · Experimental and Therapeutic Medicine
57. Protective effects of medicinal plant against diabetes induced cardiac disorder: A review
    Sadegh Shabab, Zahra Gholamnezhad, Maryam Mahmoudabady · 2020 · Journal of Ethnopharmacology
58. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
    Qutuba G. Karwi, Kim L. Ho, Simran Pherwani, Ezra B. Ketema, Qiuyu Sun, Gary D. Lopaschuk · 2021 · Cardiovascular Research
59. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
    Javier Morales, Yehuda Handelsman · 2023 · Journal of the American College of Cardiology
60. Contemporary pharmacological treatment and management of heart failure
    Biykem Bozkurt · 2024 · Nature Reviews Cardiology
61. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V
    Ferrannini, Giulia, De Bacquer, Dirk, De Backer, Guy, Kotseva, Kornelia, Mellbin, Linda, Wood, David, Rydén, Lars, EUROASPIRE V collaborators, Gale, Christopher P., Beleslin, Branko et al. · 2020 · Diabetes Care
62. Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
    Vergès, Bruno, Duvillard, Laurence, Pais de Barros, Jean Paul, Bouillet, Benjamin, Baillot-Rudoni, Sabine, Rouland, Alexia, Sberna, Anne-Laure, Petit, Jean-Michel, Degrace, Pascal, Demizieux, Laurent · 2018 · Arteriosclerosis, Thrombosis, and Vascular Biology
63. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
    Anholm, Christian, Kumarathurai, Preman, Pedersen, Lene Rørholm, Samkani, Amirsalar, Walzem, Rosemary L., Nielsen, Olav Wendelboe, Kristiansen, Ole Peter, Fenger, Mogens, Madsbad, Sten, Sajadieh, Ahmad et al. · 2019 · Atherosclerosis
64. Metabolic, structural and biochemical changes in diabetes and the development of heart failure
    Kim L. Ho, Qutuba G. Karwi, David Connolly, Simran Pherwani, Ezra B. Ketema, John R. Ussher, Gary D. Lopaschuk · 2022 · Diabetologia
65. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
    Massimo Volpe, Giovanna Gallo · 2023 · Frontiers in Cardiovascular Medicine
66. Predicting and preventing heart failure in type 2 diabetes
    Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, Deepak L. Bhatt, Subodh Verma · 2023 · The Lancet Diabetes & Endocrinology
67. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
    Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, Maxime Taquet, Amanda Adler, Ivan G. Koychev, Rachel Upthegrove, Marco Solmi, Robert Ali McCutcheon, Toby Pillinger et al. · 2025 · Nature Mental Health
68. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program
    Steinberg, William M., Rosenstock, Julio, Wadden, Thomas A., Donsmark, Morten, Jensen, Christine B., DeVries, J. Hans · 2017 · Diabetes Care
69. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
    Lundkvist, Per, Pereira, Maria J., Katsogiannos, Petros, Sjöström, C. David, Johnsson, Eva, Eriksson, Jan W. · 2017 · Diabetes, Obesity and Metabolism
70. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial
    Tronieri, Jena Shaw, Wadden, Thomas A., Walsh, Olivia, Berkowitz, Robert I., Alamuddin, Naji, Gruber, Kathryn, Leonard, Sharon, Bakizada, Zayna M., Chao, Ariana M. · 2020 · International Journal of Obesity
71. Current perspectives on cardiovascular outcome trials in diabetes
    on behalf of the D&CVD EASD Study Group, Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello · 2016 · Cardiovascular Diabetology
72. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
    David S.H. Bell, Edison Gonçalves · 2019 · Diabetes Obesity and Metabolism
73. Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control
    Flavia L. Martins, Matthew A. Bailey, Adriana C. C. Girardi · 2020 · Hypertension
74. Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History
    Hideaki Kaneto, Tomohiko Kimura, Atsushi Obata, Masashi Shimoda, Kohei Kaku · 2021 · International Journal of Molecular Sciences
75. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
    Sterling, Jacob, Hua, Peiying, Dunaief, Joshua L, Cui, Qi N, VanderBeek, Brian L · 2023 · British Journal of Ophthalmology
76. High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study
    Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Mitsutaka Nakashima, Takashi Miki, Takahiro Nishihara, Hironobu Toda, Masatoki Yoshida, Hiroshi Ito · 2022 · Cardiovascular Diabetology
77. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
    Pan, Heng-Chih, Chen, Jui-Yi, Chen, Hsing-Yu, Yeh, Fang-Yu, Sun, Chiao-Yin, Huang, Thomas Tao-Min, Wu, Vin-Cent · 2024 · Nature Communications
78. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
    Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim et al. · 2024 · Diabetes & Metabolism Journal
79. Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
    Sanjay Basu, Sridharan Raghavan, Deborah J. Wexler, Seth A. Berkowitz · 2017 · Diabetes Care
80. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
    Zheng, Deqiang, Li, Ning, Hou, Rui, Zhang, Xiaoyu, Wu, Lijuan, Sundquist, Jan, Sundquist, Kristina, Ji, Jianguang · 2023 · BMC Medicine
81. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance
    Nasui Wang, Alvin Wai Kit Tan, Linda A. Jahn, Lee M. Hartline, James T. Patrie, Shaoda Lin, Eugene J. Barrett, Kevin W. Aylor, Zhenqi Liu · 2019 · Diabetes Care
82. GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
    Lili Zhang, Jiali Tian, Sujuan Diao, Guowei Zhang, Mochao Xiao, Dong Chang · 2020 · Chemico-Biological Interactions
83. Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases
    Ibrahim AlZaim, Safaa H. Hammoud, Houssam Al-Koussa, Alaa Ghazi, Ali Hussein Eid, Ahmed Fawzy EL‐Yazbi · 2020 · Frontiers in Cardiovascular Medicine
84. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Francesco Prattichizzo, Paola de Candia, Antonio Ceriello · 2021 · Metabolism
85. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
    Konig, Manige, Riddle, Matthew C., Colhoun, Helen M., Branch, Kelley R., Atisso, Charles M., Lakshmanan, Mark C., Mody, Reema, Raha, Sohini, Gerstein, Hertzel C. · 2021 · Cardiovascular Diabetology
86. 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care
    Kim K. Birtcher, Larry A. Allen, Jeffrey L. Anderson, Marc P. Bonaca, Ty J. Gluckman, Aliza Hussain, Mikhail Kosiborod, Laxmi S. Mehta, Salim S. Virani · 2022 · Journal of the American College of Cardiology
87. The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
    Withaar, Coenraad, Meems, Laura M.G., Nollet, Edgar E., Schouten, E. Marloes, Schroeder, Marie A., Knudsen, Lotte B., Niss, Kristoffer, Madsen, Christian T., Hoegl, Annabelle, Mazzoni, Gianluca et al. · 2023 · JACC: Basic to Translational Science
88. Guidelines on the management of arterial hypertension and related comorbidities in Latin America
    Task Force of the Latin American Society of Hypertension · 2017 · Journal of Hypertension
89. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review
    Eylem Levelt, Gaurav Singh Gulsin, Stefan Neubauer, Gerry Patrick McCann · 2018 · European Journal of Endocrinology
90. Cardiovascular Disease and Diabetic Kidney Disease
    Muhammad Maqbool, Mark Emmanuel Cooper, Karin Agnes Maria Jandeleit-Dahm · 2018 · Seminars in Nephrology
91. Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
    Eleftheriadou, Aikaterini, Riley, David, Zhao, Sizheng S., Austin, Philip, Hernández, Gema, Lip, Gregory Y. H., Jackson, Timothy L., Wilding, John P. H., Alam, Uazman · 2024 · Diabetologia
92. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
    Douros, Antonios, Filion, Kristian B., Yin, Hui, Yu, Oriana Hoi, Etminan, Mahyar, Udell, Jacob A., Azoulay, Laurent · 2018 · Diabetes Care
93. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
    Volpe, Sara, Lisco, Giuseppe, Fanelli, Margherita, Racaniello, Davide, Colaianni, Valentina, Lavarra, Valentina, Triggiani, Domenico, Crudele, Lucilla, Triggiani, Vincenzo, Sabbà, Carlo et al. · 2023 · Frontiers in Endocrinology
94. Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis
    Clemens, Kristin K., Woodward, Mark, Neal, Bruce, Zinman, Bernard · 2020 · Diabetes Care
95. How glucagon-like peptide 1 receptor agonists work
    Andreasen, Christine Rode, Andersen, Andreas, Knop, Filip Krag, Vilsbøll, Tina · 2021 · Endocrine Connections
96. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
    Masato Nakamura, Hitoshi Yaku, Junya Ako, Hirokuni Arai, Tohru Asai, Taishiro Chikamori, Hiroyuki Daida, Kiyoshi Doi, Toshihiro Fukui, Toshiaki Ito et al. · 2022 · Institutional Repositories DataBase (IRDB)
97. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
    Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle · 2017 · Journal of the American Society of Nephrology
98. Graphene Aerogel Broken to Fragments for a Piezoresistive Pressure Sensor with a Higher Sensitivity
    Congxing Yang, Weijie Liu, Nishuang Liu, Jun Su, Luying Li, Lun Xiong, Fei Long, Zhengguang Zou, Yihua Gao · 2019 · ACS Applied Materials & Interfaces
99. The right place for metformin today
    Guntram Schernthaner, Gerit-Holger Schernthaner · 2019 · Diabetes Research and Clinical Practice
100. The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy
     Malak Ghazi Almutairi, Keshav Gopal, Amanda A. Greenwell, Adrian Young, Robert Gill, Hanin Aburasayn, Rami Al Batran, Jadin J. Chahade, Manoj Gandhi, Farah Eaton et al. · 2020 · Canadian Journal of Cardiology